Matribhumi Samachar English
Boca Raton, Florida–(Newsfile Corp. – August 14, 2025) – Entero Therapeutics, Inc. (NASDAQ: ENTO) (the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that, it will effect a 1 for 3 reverse stock split of its common stock. The Company expects …
Read More »Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
Boca Raton, Florida–(Newsfile Corp. – August 11, 2025) – Entero Therapeutics, Inc. (NASDAQ: ENTO) (the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of …
Read More »Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC
Boca Raton, Florida–(Newsfile Corp. – March 24, 2025) – Entero Therapeutics, Inc. (NASDAQ: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the “Rescission Agreement”) with …
Read More »